ストックスクリーナーアプリを入手
512.88
1.41%
7.13
Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Madrigal Pharmaceuticals Stockweekly review and NASH sector context - AD HOC NEWS
Madrigal Pharmaceuticals Inc - TradingKey
Madrigal Pharmaceuticals Inc (MDGL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Madrigal Pharmaceuticals Inc (MDGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Madrigal Shareholders Approve 2026 Equity Compensation Plans - The Globe and Mail
[Form 4] MADRIGAL PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Madrigal (MDGL) director Richard Levy receives new RSU and stock option grants - Stock Titan
Madrigal Pharmaceuticals (MDGL) director granted RSUs and stock options - Stock Titan
Madrigal (MDGL) director James Daly granted RSUs and 766-share option - Stock Titan
Madrigal (MDGL) director receives stock grants and 681-share option award - Stock Titan
Madrigal (MDGL) Baker Bros.-aligned directors receive RSU and option awards - Stock Titan
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals shareholders approve new equity plans and board changes By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals shareholders approve new equity plans and board changes - Investing.com Nigeria
Madrigal (NASDAQ: MDGL) updates equity, ESPP and deferred pay plans - Stock Titan
Madrigal Pharmaceuticals Inc (MDGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Madrigal Cooperating With NICE On MASH Drug After Provisional English Funding Rejection - Citeline News & Insights
Price-Driven Insight from (MDGL) for Rule-Based Strategy - Stock Traders Daily
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Globe and Mail
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Madrigal Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Madrigal (MDGL) down 7.9% since last earnings report: Can it rebound? - MSN
MDGL Maintained by B of A Securities -- Price Target Lowered to $542 - GuruFocus
BofA cuts Madrigal Pharmaceuticals price target on competition concerns By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals launches 'MASH Across America' with giant inflatable liver in Philly - PharmaLive
MDGL: Rezdiffra’s blockbuster launch and expanding pipeline position the company for sustained growth - TradingView
Madrigal Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
MDGL Q1 2026 Earnings: Narrower Loss Surprises MarketsEarnings Yield Spread - lwvtexas.org
Madrigal Investors Focus on Rezdiffra Growth at Goldman Event - MyChesCo
The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Exploring A 39% Upside Potential - DirectorsTalk Interviews
Goldman Sachs Group Inc. Trims Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Fiera Capital Corp Acquires 41,656 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Return on invested capital % of Madrigal Pharmaceuticals, Inc. – XETR:YDO1 - TradingView
Madrigal Pharmaceuticals, Inc. News — XETR:YDO1 - TradingView
Madrigal Pharmaceuticals, Inc. Statistics – XETR:YDO1 - TradingView
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Madrigal Q1 2026 slides: blockbuster Rezdiffra tops $1.1B in sales - Investing.com
(MDGL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Earnings call transcript: Madrigal Pharmaceuticals Q1 2026 surprises with earnings beat - Investing.com
Legal & General Group Plc Sells 6,440 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal (MDGL) Data Highlights Rezdiffra’s Cardiometabolic Benefits for MASH Patients at EASL Congress - Insider Monkey
Madrigal Highlights Rezdiffra Data as MASH Market Expands - MyChesCo
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 - The Manila Times
12 Best High Short Interest Stocks With Highest Upside Potential - Insider Monkey
Madrigal Pharmaceuticals targets liver disease with Rezdiffra, eyeing strong growth despite competition risks. - Pluang
Madrigal Pharmaceuticals Could Become The Next Vertex - Seeking Alpha
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness - Yahoo Finance
Madrigal Pharmaceuticals (MDGL) slides as insider sale headlines hit and investors take profits - Quiver Quantitative
Insider Sell: David Soergel Sells Shares of Madrigal Pharmaceuti - GuruFocus
Madrigal Pharmaceuticals CMO David Soergel sells $516,561 in shares By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals CMO David Soergel sells $516,561 in shares - Investing.com
0.57%
1.15%
大文字化:
|
ボリューム (24 時間):